Treating relapsing carcinoma with high-quality image-guided intensity-modulated radiation therapy using the TomoTherapy treatment system

The purpose of this study was to examine solutions to the clinical problems that are suffered by patients. By employing sequential image-guided intensity-modulated radiation therapy (herein referred to as IGIMRT), the patients were observed and compared from the perspectives of various elements: Biochemical non-evidence of disease (bNED), Prostate-Specific Antigen (PSA), Quality of Life (QOL), etc. The TomoTherapy treatment system, which facilitates delivery of IGIMRT and targets all visible malignant tumors, was utilized in this study in order to provide local control for a total of 5 patients with far advanced prostate cancer. The observation period was between 21 and 37 months.In the series of stage IV prostate cancer cases, it was possible to irradiate lesions in a single procedure in 4 of the 5 cases, including a positive lymph node and bone metastasis in addition to the primary lesion and the seminal vesicle, by employing the TomoTherapy treatment system and achieving bNED in these patients. Furthermore, in the remaining case, it was possible to achieve bNED by controlling liver metastasis that had repeated solitary recurrence. Additionally, in these cases there were a variety of responses to hormone therapy: one case of refusal from the patient, one acceptance from the patient for half a year, one acceptance for one and a half years, one case for continuance, and one refractory case.In conclusion, treatment with high-quality IGIMRT using the TomoTherapy treatment system provides scope for treating cases of relapsing tumors.